BCL2 and acute myeloid leukemia: Pre-clinical studies in de novo AML demonstrate that inhibition of B-cell lymphoma 2 (BCL-2) decreases amino acid metabolism and inhibits OXPHOS in LSCs, resulting in preferential LSC elimination and underlining the importance of targeting LSC metabolism.